Cozaar

An antagonist of angiotensin type 1 receptor with antihypertensive activity due to the reduced pressor effect of angiotensin II. .
[PubChem].

Medicinal name:
  • Losartan Potassium 25 MG Oral Tablet [Cozaar]
  • Losartan Potassium 50 MG Oral Tablet [Cozaar]
  • Losartan Potassium 100 MG Oral Tablet [Cozaar]

Cozaar - Pharmacology:

Cozaar and its longer acting active metabolite (E-3174) interfere with the binding of angiotensin II to the angiotensin II AT1-receptor by, themselves, binding reversibly to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Neither Cozaar or its metabolite inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels.

Cozaar mini report

Cozaar NDA
NDA - A product marketed under an approved New Drug Application
Cozaar TABLET
TABLET
Cozaar TABLET, FILM COATED
TABLET, FILM COATED
Cozaar HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Cozaar global name
Cozaar
Cozaar global name
losartan potassium
Start - Stop data
START DATA:
2011-Apr-07
Start - Stop data
STOP DATA
not occurred

Cozaar for patients

PATIENT INFORMATION

Cozaar potassium is used to treat high blood pressure. It may be used alone
or with other medications for high blood pressure. This medication should,
generally, not be used during pregnancy. If you are pregnant or considering
becoming pregnant, inform your physician immediately to discuss the risks
versus benefits. There are few side effects associated with losartan potassium.
Those most frequently reported, cough, upper respiratory infection and
dizziness, occurred no more frequently than in patients who did not take this
medication. You may take this medication with or without food. You should have
your blood pressure checked regularly

Cozaar Interactions

No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite. In humans, two inhibitors of P450 3A4 have been studied. Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration. Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration. The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined. Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9. These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.

As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.

As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin.

 

Cozaar Contraindications

COZAAR is contraindicated in patients who are hypersensitive to any component of this product.

Manufacturers name:

  • Merck Sharp & Dohme Corp
  • Cardinal Health
  • Physicians Total Care, Inc
  • PD-Rx Pharmaceuticals, Inc
  • REMEDYREPACK INC
  • Bryant Ranch Prepack

Generic name, Overdose, Half Life Cozaar, Food Interactions, Chemical, etc..

Cozaar see also FDA report Barrenwort

Blood Pressure
Brand Names containing Losartan